Literature DB >> 16966187

Constitutive mRNA expression of DNA repair-related genes as a biomarker for clinical radio-resistance: A pilot study in prostate cancer patients receiving radiotherapy.

Jörg Hümmerich1, Gisela Werle-Schneider, Odilia Popanda, Oktay Celebi, Jenny Chang-Claude, Silke Kropp, Claudia Mayer, Jürgen Debus, Helmut Bartsch, Peter Schmezer.   

Abstract

PURPOSE: Repair of radiation-induced DNA damage is believed to play a critical role in the development of adverse reactions in radiotherapy patients. Constitutive mRNA expression of repair genes was investigated in such patients to analyze whether expression patterns are predictive for therapy-related acute side effects.
MATERIALS AND METHODS: Prostate cancer patients (n = 406) receiving intensity-modulated radiotherapy were recruited in a prospective epidemiological study. Adverse effects were monitored during therapy using common toxicity criteria. For expression analyses, samples from 58 patients were selected according to their observed grade of clinical side effects to radiotherapy. Expression profiles were generated from peripheral blood lymphocytes using customized cDNA-arrays which carried probes for 143 DNA repair or repair-related genes. In addition, expression of selected genes was confirmed by quantitative real-time reverse transcription PCR (RT-PCR). Constitutive mRNA expression profiles were analyzed for predicting acute clinical radiosensitivity or radio-resistance.
RESULTS: Cluster analysis identified 19 differentially expressed genes. Many of these genes are involved in DNA double strand break repair. Expression levels of these genes differed up to 7-fold from the mean of all patients whereas expression levels of housekeeping genes varied only up to 2-fold. High expression of the identified genes was associated with a lack of clinical radiation sensitivity thus indicating radio-resistance.
CONCLUSIONS: Constitutive expression of DNA repair-related genes may affect the development of acute side effects in radiotherapy patients, and high expression levels of these genes seem to support protection from adverse reactions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16966187     DOI: 10.1080/09553000600883302

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  8 in total

1.  Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot study.

Authors:  J M Bowen; I White; L Smith; A Tsykin; K Kristaly; S K Thompson; C S Karapetis; H Tan; P A Game; T Irvine; D J Hussey; D I Watson; D M K Keefe
Journal:  Support Care Cancer       Date:  2015-03-27       Impact factor: 3.603

Review 2.  Molecular and Functional Diagnostic Tools in Precision Oncology for Urological Malignancies.

Authors:  Vasanthakumar Sekar; Debapriya Ghosh Mehrotra; Biswanath Majumder
Journal:  Indian J Surg Oncol       Date:  2016-12-15

Review 3.  Radiogenomics: A systems biology approach to understanding genetic risk factors for radiotherapy toxicity?

Authors:  Carsten Herskind; Christopher J Talbot; Sarah L Kerns; Marlon R Veldwijk; Barry S Rosenstein; Catharine M L West
Journal:  Cancer Lett       Date:  2016-03-02       Impact factor: 8.679

4.  alpha6 integrin cleavage: sensitizing human prostate cancer to ionizing radiation.

Authors:  Sangita C Pawar; Shona Dougherty; Michael E Pennington; Manolis C Demetriou; B Dino Stea; Robert T Dorr; Anne E Cress
Journal:  Int J Radiat Biol       Date:  2007 Nov-Dec       Impact factor: 2.694

5.  Screening the key microRNAs and transcription factors in prostate cancer based on microRNA functional synergistic relationships.

Authors:  Fan Feng; Jitao Wu; Zhenli Gao; Shengqiang Yu; Yuanshan Cui
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

6.  Simvastatin Sensitizes Radioresistant Prostate Cancer Cells by Compromising DNA Double-Strand Break Repair.

Authors:  Yu-An Chen; Hua-Wei Shih; Yi-Chun Lin; Hui-Ying Hsu; Tsu-Fang Wu; Chen-Han Tsai; Chia-Lin Wu; Hui-Yu Wu; Jer-Tsong Hsieh; Chih-Hsin Tang; Chih-Ho Lai
Journal:  Front Pharmacol       Date:  2018-06-13       Impact factor: 5.810

7.  Sensitization of radio-resistant prostate cancer cells with a unique cytolethal distending toxin.

Authors:  Chih-Ho Lai; Chia-Shuo Chang; Hsin-Ho Liu; Yuh-Shyan Tsai; Feng-Ming Hsu; Yung-Luen Yu; Cheng-Kuo Lai; Leah Gandee; Rey-Chen Pong; Heng-Wei Hsu; Lan Yu; Debabrata Saha; Jer-Tsong Hsieh
Journal:  Oncotarget       Date:  2014-07-30

Review 8.  Improving radiotherapy in cancer treatment: Promises and challenges.

Authors:  Helen H W Chen; Macus Tien Kuo
Journal:  Oncotarget       Date:  2017-06-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.